Dream merger: Guidant lashes out after J&J turns its back on deal
This article was originally published in Clinica
The "dream" merger that could have created the largest cardiac powerhouse in medtech history has now disintegrated and led to a legal standoff. Guidant filed a lawsuit against Johnson & Johnson on Monday (November 7) to force the healthcare giant into going through with the original $25.4bn acquisition plan that the two companies had entered into in December last year.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.